Olokizumab 64 mg SC q4w ( DrugBank: Olokizumab )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03120949 (ClinicalTrials.gov) | July 4, 2017 | 7/2/2017 | Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis | A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Olokizumab 64 mg SC q4w;Drug: Olokizumab 64 mg SC q2w | R-Pharm International, LLC | IQVIA Pvt. Ltd;OCT Clinical Trials | Completed | 18 Years | N/A | All | 2106 | Phase 3 | United States;Argentina;Belarus;Brazil;Bulgaria;Colombia;Czechia;Estonia;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;Korea, Republic of;Germany;Hungary |